![](/img/cover-not-exists.png)
End of dose interval symptoms in patients treated with natalizumab: a role for serum cytokines?
Cathérine, Dekeyser, Annelien, De Pue, Anne, Sieben, Luc, Algoed, Liesbeth, Van Hijfte, Gerlo, Sarah, Guy, LaureysLanguage:
english
Journal:
Multiple Sclerosis and Related Disorders
DOI:
10.1016/j.msard.2020.102020
Date:
February, 2020
File:
PDF, 808 KB
english, 2020